Each molecularly defined diagnostic group, i.e. IDH-mutant astrocytomas or oligodendrogliomas, histone-mutant gliomas, BRAF-mutant gliomas and ependymomas will be discussed separately with an emphasis on the specific molecular alterations in each group and their clinical relevance. Here, IDH2 is linked to glioma.